Loading...
XSHE
300238
Market cap441mUSD
Jul 09, Last price  
11.29CNY
1D
-2.34%
1Q
-26.50%
Jan 2017
-66.15%
IPO
11.73%
Name

Guanhao Biotech Co Ltd

Chart & Performance

D1W1MN
XSHE:300238 chart
P/E
122.96
P/S
7.81
EPS
0.09
Div Yield, %
Shrs. gr., 5y
0.15%
Rev. gr., 5y
-4.75%
Revenues
383m
+1.57%
35,192,06065,569,016102,618,066128,510,115147,020,069168,501,934190,356,664226,172,525312,789,660460,596,556458,461,848437,886,453436,957,168488,981,886488,981,886377,285,014377,285,014404,178,697377,483,103383,422,023
Net income
24m
-11.20%
7,094,82214,416,92132,341,05940,422,52037,031,45140,573,89850,103,15163,366,04656,955,82745,523,13545,746,536-465,329,80846,594,90773,687,00673,687,0120-307,824,82731,005,80327,416,91524,346,028
CFO
71m
+44.23%
1,727,9884,802,7825,551,30333,755,38335,453,97949,124,92041,487,99565,448,67167,865,96230,680,82119,218,21532,276,11692,545,564103,839,533122,394,24370,983,73054,149,82749,554,79671,473,795
Dividend
Jun 20, 20180.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guanhao Biotech Co.,Ltd. is a Chinese enterprise dedicated to the research, production, and marketing of regenerative medicine solutions. Its product portfolio encompasses NormalGEN, a biological dura repair patch crafted from animal tissue, and GrandNeuro, an artificial alternative for dura restoration. For broader surgical applications, the company offers ThormalGEN, another biological surgical patch also derived from animal tissue. DermalGEN, an animal tissue-based wound dressing, is designed for treating burns, scalds, and skin injuries resulting from loss or trauma. Additionally, Guanhao Biotech markets the IREAL breast patch. The company was established in 1999 and is headquartered in Guangzhou, China.
IPO date
Jul 06, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT